Larimar Therapeutics
Clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
- Location
- —
- Roles tracked
- 0
- In pipeline
- 0
- Tracking since
- —
At a glance
You're tracking 0 roles at Larimar Therapeutics. Track a role to start building momentum here.
Company intel
From the job board · LinkedIn data via posting sync- Industry
- Biotechnology
- Company size
- 87 people
- Headquarters
- Bala Cynwyd, PA +1 more
- Founded
- 2016
- Type
- Public Company
- Total funding
- $721.7M
Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
